Corvus Pharmaceuticals (CRVS) Cash from Investing Activities (2015 - 2026)

Corvus Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at -$144.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 3513.76% year-over-year to -$144.8 million; the TTM figure through Mar 2026 stood at -$156.9 million (down 575.24% YoY), while the FY2025 annual figure was -$7.8 million, up 71.63% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$144.8 million, down from $10.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $17.5 million in Q3 2023, with the low at -$144.8 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is -$2.6 million (2025), against an average of -$11.1 million.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities jumped 60714.29% in 2025, then plunged 3513.76% in 2026.
• Corvus Pharmaceuticals' Cash from Investing Activities stood at -$3.9 million in 2022, then surged by 40.29% to -$2.3 million in 2023, then plunged by 162.42% to -$6.1 million in 2024, then soared by 278.86% to $10.9 million in 2025, then plunged by 1431.31% to -$144.8 million in 2026.
• Business Quant data shows CRVS's Cash from Investing Activities at -$144.8 million in Q1 2026, $10.9 million in Q4 2025, and -$2.6 million in Q3 2025.